您的位置: 首页 > 农业专利 > 详情页

Stabilized formulation of ivermectin feed premix
专利权人:
Merial; Inc.
发明人:
FREEHAUF, Keith Allan
申请号:
ES04814670
公开号:
ES2664974T3
申请日:
2004.12.17
申请国别(地区):
ES
年份:
2018
代理人:
摘要:
A premix for an animal feed that has a long shelf life comprising: a) 0.04 to 5% (w / w) of at least one avermectin compound; b) a pharmaceutically acceptable excipient comprising: i) 5 to 15% (w / w) of a surfactant in which said surfactant is selected from the group consisting of polyoxyl 40 hydrogenated castor oil, PEG-50 castor oil, PEG-60 corn glyceride, PEG-60 almond oil, PEG-40 palm almond oil and PEG-60 corn oil; ii) 5 to 25% (w / w) of a wax in which said wax is selected from the group consisting of distilled monoglycerides, glyceryl tribehenate, glyceryl trimiristate and hydrogenated coco glycerides; iii) 0.1 to 2% (w / w) of an antioxidant in which said antioxidants are selected from the group consisting of butylated hydroxyanisole, butylated hydroxytoluene, ascorbic acid, sodium metabisulfite, propyl gallate, sodium thiosulfate and a mixture thereof; iv) 60 to 80% (w / w) of a pharmaceutically acceptable vehicle in which said vehicle is selected from the group consisting of finely ground corn cobs, crushed limestone and dried grains; c) a pharmaceutically acceptable stabilizer in an amount effective to adjust the pH of the premix formulation in a range of 4 to 6 to decrease the acid or base catalyzed decomposition of at least one avermectin compound, wherein said stabilizer is acidic Anhydrous citrus present in an amount of 0.3 to 1.5% (w / w); and d) optionally, an effective amount of at least one insect growth regulator compound selected from the group consisting of meprene, pyriproxyphene, hydroprene, ciromazine, lufenuron, 1- (2,6-difluorobenzoyl) -3- (2-fluoro- 4- (trifluoromethyl)) phenylurea, novaluron and a mixture thereof.Una premezcla para un pienso para animales que presenta una vida útil prolongada que comprende: a) del 0,04 al 5 % (p/p) de al menos un compuesto de avermectina; b) un excipiente farmacéuticamente aceptable que comprende: i) del 5 al 15 % (p/p) de un tensioactivo en el que dicho tensioactivo se selecciona del grupo que consiste
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充